Fluticasone and N-acetylcysteine in primary care patients with COPD or chronic bronchitis

Respiratory Medicine

Volumn 103, Issue 4, 2009, Pages 542-551

  Schermer, Tjard ^a   Chavannes, Niels ^b   Dekhuijzen, Richard ^a   Wouters, Emiel ^c   Muris, Jean ^b   Akkermans, Reinier ^a   van Schayck, Onno ^b   van Weel, Chris ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Chronic obstructive pulmonary disease; Exacerbation; Inhaled steroids; N acetylcysteine; Primary care; Quality of life

Indexed keywords

ACETYLCYSTEINE; FLUTICASONE PROPIONATE; PLACEBO; PREDNISOLONE; ANDROSTANE DERIVATIVE; BRONCHODILATING AGENT; EXPECTORANT AGENT; FLUTICASONE;

ADULT; ARTICLE; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG EFFICACY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PHASE 4 CLINICAL TRIAL; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SMOKING; TREATMENT OUTCOME; AGED; BRONCHITIS, CHRONIC; COMPARATIVE STUDY; MIDDLE AGED; MULTICENTER STUDY; NETHERLANDS; PRIMARY HEALTH CARE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

ACETYLCYSTEINE; ADULT; AGED; ANDROSTADIENES; BRONCHITIS, CHRONIC; BRONCHODILATOR AGENTS; EXPECTORANTS; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; NETHERLANDS; PRIMARY HEALTH CARE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; SMOKING; TREATMENT OUTCOME;

EID: 60649103762     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2008.11.003     Document Type: Article

References (39)

1. Feenstra T.L., van Genugten M.L., Hoogenveen R.T., Wouters E.F., and Rutten-van Molken M.P. The impact of aging and smoking on the future burden of chronic obstructive pulmonary disease: a model analysis in the Netherlands. Am J Respir Crit Care Med 164 4 (2001) 590-596
2. Barnes P.J., Shapiro S.D., and Pauwels R.A. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J 22 4 (2003) 672-688
3. Dekhuijzen P.N. Antioxidant properties of N-acetylcysteine: their relevance in relation to chronic obstructive pulmonary disease. Eur Respir J 23 4 (2004) 629-636
4. Stey C., Steurer J., Bachmann S., Medici T.C., and Tramer M.R. The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review. Eur Respir J 16 (2000) 253-262
5. Poole P.J., and Black P.N. Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review. BMJ 322 (2001) 1-6
6. Grandjean E.M., Berthet P., Ruggieri M.P., and Leuenberger P. Efficacy of oral long-term N-acetylcysteine in chronic broncho-pulmonary disease: a meta-analysis of published double-blind, placebo-controlled clinical trials. Clin Ther 22 2 (2000) 209-221
7. Decramer M., Rutten-van Molken M., Dekhuijzen P.N., Troosters T., van Herwaarden C., Pellegrino R., et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet 365 9470 (2005) 1552-1560
8. Hattotuwa H.L., Gizycki M.J., Ansari T.W., Jeffery B.K., and Barnes N.C. The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study. Am J Respir Crit Care Med 165 (2002) 1579-1580
9. 1 in patients with chronic obstructive pulmonary disease. A meta-analysis. Ann Intern Med 138 12 (2003) 969-973
10. Sutherland E.R., Allmers H., Ayas N.T., Venn A.J., and Martin R.J. Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: a meta-analysis. Thorax 58 11 (2003) 937-941
11. Alsaeedi A., Sin D.D., and McAlister F.A. The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. Am J Med 113 1 (2002) 59-65
12. Siafakas N.M., Vermeire P., Pride N.B., Paoletti P., Gibson J., Howard P., et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European respiratory society task force. Eur Respir J 8 8 (1995) 1398-1420
13. Guyatt G.H., Berman L.B., Townsend M., Pugsley S.O., and Chambers L.W. A measure of quality of life for clinical trials in chronic lung disease. Thorax 42 10 (1987) 773-778
14. Burge P.S., Calverley P.M.A., Jones P.W., Spencer S., Anderson J.A., and Maslen T.K. Randomised, double blind placebo controlled study of fluticasone propionate in patiens with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 320 (2000) 1297-1303
15. Dompeling E., van Schayck C.P., Molema J., Folgering H., van Grunsven P.M., and van Weel C. Inhaled beclomethasone improves the course of asthma and COPD. [see comments]. Eur Respir J 5 (1992) 945-952
16. Renkema T.E.J., Schouten P.J., Koeter G.H., and Postma D.S. Effects of long-term treatment with corticosteroids in COPD. Chest 109 (1996) 1156-1162
17. Rutten-van Molken M., Roos B., and Van Noord J.A. An empirical comparison of the St George's respiratory questionnaire (SGRQ) and the chronic respiratory disease questionnaire (CRQ) in a clinical trial setting. Thorax 54 11 (1999) 995-1003
18. Pauwels R.A., Lofdahl C.G., Laitinen L.A., Schouten J.P., Postma D.S., Pride N.B., et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N Engl J Med 340 (1999) 1948-1953
19. Vestbo J., Sorensen T., Lange P., Brix A., Torre P., and Viskum K. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 353 (1999) 1819-1823
20. Quanjer P.H., Tammeling G.J., Cotes J.E., Pedersen O.F., Peslin R., and Yernault J.C. Lung volumes and forced ventilatory flows. Report working party standardization of lung function tests, European community for steel and coal. Official statement of the european respiratory society. [see comments]. Eur Respir J Suppl 16 s (1993) 5-40
21. Maille A.R., Koning C.J., Zwinderman A.H., Willems L.N., Dijkman J.H., and Kaptein A.A. The development of the 'Quality-of-life for Respiratory Illness Questionnaire (QOL-RIQ)': a disease-specific quality-of-life questionnaire for patients with mild to moderate chronic non-specific lung disease. Respir Med 91 5 (1997) 297-309
22. Suissa S. Statistical treatment of exacerbations in therapeutic trials of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 173 8 (2006) 842-846
23. Aaron S.D., Fergusson D., Marks G.B., Suissa S., Vandemheen K., Doucette S., et al. Counting, analyzing and reporting exacerbations of COPD in randomized, controlled trials. Thorax 63 2 (2008) 122-128
24. Global initiative for chronic obstructive lung disease (GOLD). ; 2006 [accessed 17.09.07]. Unpublished work.
25. Schermer T.R.J., Hendriks A.J.C., Chavannes N.H., Dekhuijzen P.N.R., Wouters E.F.M., van den Hoogen H.J., et al. Probability and determinants of relapse after discontinuation of inhaled corticosteroids in patients with COPD treated in general practice. Prim Care Respir J 13 (2004) 48-55
26. Calverley P.M., Burge P.S., Spencer S., Anderson J.A., and Jones P.W. Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax 58 8 (2003) 659-664
27. 1 in patients with COPD after all?. Thorax 58 11 (2003) 911-913
28. Wise M.D., Connet J., Weinmann G., Scanlon P., and Skeans M. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 343 (2000) 1902-1909
29. Calverley P.M., Anderson J.A., Celli B., Ferguson G.T., Jenkins C., Jones P.W., et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 356 8 (2007) 775-789
30. Osman L.M., Godden D.J., Friend J.A.R., Legge J.S., and Douglas J.G. Quality of life and hospital re-admission in patients with chronic obstructive pulmonary disease. Thorax 52 (1997) 67-71
31. Schunemann H.J., Griffith L., Jaeschke R., Goldstein R., Stubbing d., Austin P., et al. A comparison of the original chronic respiratory questionnaire with a standardized version. Chest 124 4 (2003) 1421-1429
32. van der Valk P., Monninkhof E., van der Palen J., Zielhuis G., and van Herwaarden C. Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study. Am J Respir Crit Care Med 166 10 (2002) 1358-1363
33. Oostenbrink J.B., Rutten-van Molken M.P., Al M.J., Van Noord J.A., and Vincken W. One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease. Eur Respir J 23 2 (2004) 241-249
34. Calverley P., Pauwels R., Vestbo J., Jones P., Pride N., Gulsvik A., et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 361 9356 (2003) 449-456
35. O'Brien A., Russo-Magno P., Karki A., Hiranniramol S., Hardin M., Kaszuba M., et al. Effects of withdrawal of inhaled steroids in men with severe irreversible airflow obstruction. Am J Respir Crit Care Med 164 (2001) 365-371
36. Wouters E.F., Postma D.S., Fokkens B., Hop W.C., Prins J., Kuipers A.F., et al. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial. Thorax 60 6 (2005) 480-487
37. Jarad N.A., Wedzicha J.A., Burge P.S., and Calverley P.M. An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. Respir Med 93 3 (1999) 161-166
38. Hoogendoorn M., Feenstra T.L., Schermer T.R.J., Hesselink A.E., and Rutten-van Molken M.P.H. Severity distribution of chronic obstructive pulmonary disease (COPD) in Dutch general practice. Respir Med 100 1 (2006) 83-86
39. Celli B.R., and MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 23 6 (2004) 932-946